Although CTC count in patients with GC may act as an early biomarker for the determination of therapeutic efficacy, the prognostic significant of CTC molecular profiling, including determination of MDM2, c-MYC, and HER2 status in CTC, is less determined in GC patients. This evidence concerns the gene ERBB2 and gastric cancer.